Inflammatory Bowel Diseases

Skip Navigation LinksHome > February 2009 - Volume 15 - Issue 2 > Co‐prescribing azathiopurine or 6‐mercaptopurine and 5‐amino...
Inflammatory Bowel Diseases:
doi: 10.1002/ibd.20750
Original Article

Co‐prescribing azathiopurine or 6‐mercaptopurine and 5‐aminosalicylate compounds in ulcerative colitis

Mayberry, H.1; Moshkovska, T. MD1; Mayberry, J. F. MD1*

Collapse Box


Background:: A total of 254 senior consultant gastroenterologists with valid e‐mail addresses were identified from the membership list of the British Society of Gastroenterology (BSG) 2007.

Methods:: They were sent by e‐mail a questionnaire which dealt with aspects of clinical practice and addressed cancer prevention in ulcerative colitis (UC). Replies were received from 97 clinicians (38% response rate).

Results:: Ninety‐one (94%) advised patients with established UC to take 5‐aminosalicylate (5‐ASA) compounds for life. Seventy‐two of the 91 (79%) clinicians co‐prescribed 5‐ASA compounds with immune modulators for patients with UC. Only 3 clinicians advised patients to take folic acid as a daily supplement. A median of 20% (interquartile range 10%–50%) of their patients with UC were co‐prescribed a 5‐ASA compound and azathioprine or 6‐mercaptopurine. Of these, a median of 3.5% (interquartile 1%–5%) developed neutropenia.

Conclustions:: Future research needs to be directed at the long‐term maintenance treatment and to address questions about which drugs should be used, in what combinations, and with what frequencies.

© Crohn's & Colitis Foundation of America, Inc.

You currently do not have access to this article.

You may need to:

Note: If your society membership provides for full-access to this article, you may need to login on your society’s web site first.


Article Tools


Article Level Metrics

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.